Arch Pharm Pharm Med Chem 332:389–398CrossRef Walczyński K, Zuiderveld OP, Timmerman H (2005) Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists. Eur J Med Chem 40:15–23PubMedCrossRef Yokatoni K, Murakami Y, Okada S, Wang M, Nakamura K (2000) Histamine H(3) receptor-mediated inhibition of endogenous acetylcholine release from the isolated, vascularly perfused rat stomach. Eur J Pharmacol 392:23–29CrossRef Zhang M, Ballard ME, Pan
P, Roberts S, Faghih R, Cowart MD, Esbenshade Inhibitor Library screening TA, Fox G, Decker MW, Hancock AA, Rueter LE (2005) Lack of cataleptogenic potentiation with non-imidazole H3 Selleckchem Belnacasan receptor antagonists reveals potential drug–drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res 1045:142–149PubMedCrossRef”
“Introduction For the last few decades, there has been a tremendous growth of research in the synthesis of nitrogen and sulfur containing heterocyclic derivatives because of their utility in various applications, such as pharmaceuticals, propellants, explosives, and pyrotechnics. The recent literature is enriched with progressive findings about the Selumetinib clinical trial synthesis and pharmacological action of triazole
and thiadiazole derivatives. Heterocycles bearing 1,2,4-triazole and 1,3,4-thiadiazole moiety are reported to show a broad spectrum of biologic activity such as analgesic (Turan-Zitouni Rucaparib molecular weight et al., 1999), antiphlogistic (Harish et al., 2008; El Shehry et al., 2010; Schenone et al., 2006), anticonvulsant (Dogan et al., 2002; Almasirad et al., 2004), antitumor (Duran et al., 2002; Kumar et al., 2010), antiviral (Al-Soud et al., 2004), antifungal (Collin et al., 2003; Wei et al., 2006), antibacterial (Ulusoy et al.,
2001; Gülerman et al., 2001; Padmavathi et al., 2009; Demirbas et al., 2009; Liesen et al., 2010), and antitubercular action (Klimešová et al., 2004; Gadad et al., 2004; Shiradkar et al., 2007). A large number of ring systems containing triazoles and thiadiazoles have been incorporated into a wide variety of therapeutically interesting drug candidates. Some of them are approved as drugs, for example, alprazolam (Pick, 1997), etizolam (Shiroki et al., 1976), or vibunazole (Holmwood et al., 1982). Vorozole, letrozole, and anastrozole are non-steroidal drugs used for the treatment of cancer (Clemons et al., 2004). Triazoles are also used as intermediates for the synthesis of antifungal agents such as fluconazole, voriconazole, and itraconazole (Bailey et al., 1990; McGinnis et al., 1997).